mv-1

MV1 是一种 IAP 拮抗剂。 当与 HaloTag 配体结合时，它会导致 HaloTag 融合蛋白的蛋白质敲低。

MV-1-NH-Me, an MV-1-derived IAP ligand, connects to an ABL inhibitor through a linker, resulting in the formation of SNIPER[1].

JMV-1645 is an effective and selective B(1) bradykinin receptor antagonist.

JMV-1609 is a bioactive chemical.

MV151 是一种具有细胞渗透性的荧光广谱蛋白酶体抑制剂，特异性靶向活细胞中蛋白酶体和免疫蛋白酶体的所有活性亚基，可用于体外和体内标记蛋白酶体。

MMV1088447是一种新型寄生虫生长抑制剂。此化合物在特性上与处理过核激素受体 (NHR) 激动剂 拮抗剂的细胞相似。通过减少宿主的脂质代谢，MMV1088447能够显著抑制寄生虫生长。

Jmv 167 is an antagonist of the Cholecystokinin receptor.

Jmv 170 is the C-terminal heptapeptide of cholecystokinin. It has partial agonist CCK activity on pancreatic amylase release.

Jmv 179 is an antagonist of the cholecystokinin receptor.

Jmv 176 is a CCK agonist when first given and becomes a cholecystokinin antagonist after 3-4 hours.

Jmv 180, a CCK analog, can distinguish high-affinity cholecystokinin receptors from low-affinity cholecystokinin receptors.

Macimorelin (EP-1572) acetate，一种 GH 促分泌素，是一种具有口服活性的GHSR 激动剂。Macimorelin acetate 可刺激 GH 的释放。Macimorelin acetate 可用于成人生长激素缺乏症 (AGHD) 和癌症厌食-恶病质综合征 (CACS) 的研究。

MMV1557817 具有口服活性的化合物，有效对抗疟疾。该化合物针对恶性疟原虫和间日疟原虫的氨基肽酶M1及M17表现出良好的选择性抑制作用，能有效阻断无性疟原虫在其生命周期终末期对血红蛋白的消化过程。

MMV1634566,作为一种高效的抗疟疾化合物,能够抑制Plasmodium falciparum,并具有细胞毒性.

Poly(acrylic acid) (Mv 100000) 一种在生化反应中使用的试剂。

GNE-207 is a selective and orally bioavailable inhibitor of the bromodomain of CBP (IC50: 1 nM). It has a selective index of >2500-fold against BRD4 (1). GNE-207 displays excellent CBP potency (EC50: 18 nM for MYC expression in MV-4-11 cells).

SNIPER(ABL)-015, conjugating GNF5 (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 5 μM [1].

SNIPER(ABL)-019, conjugating Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 0.3 μM[1].

SNIPER(ABL)-047, conjugating HG-7-85-01 (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 2 μM[1].

SNIPER(ABL)-050 is a chemical compound that combines Imatinib, an ABL inhibitor, with MV-1, an IAP ligand, using a linker. This conjugation results in the reduction of BCR-ABL protein[1].

FLT3 HDAC-IN-1作为一种对FLT3和HDAC具有抑制作用的双重抑制剂，其对FLT3、HDAC1和HDAC3的IC50分别为30.4 nM、52.4 nM、14.7 nM。该化合物在MV-4-11细胞中能够诱导细胞凋亡(apoptosis)，且对携带FLT3突变的BaF3细胞表现出显著的抗增殖效果。FLT3 HDAC-IN-1因此适用于难治性实体瘤及血液系统恶性肿瘤的科研应用。

THP-1 MV-4-11 against-1 (compound 12k) 是一种 5-取代噻唑基脲类抗癌剂，对 THP-1 MV-4-11 癌细胞显示出显著的抑制作用 (IC50 分别为 29 nM 和 98 nM)。

ORY-1001 is a KDM1A inhibitor (IC50 <20nM) with high selectivity against related FAD dependent aminoxidases (MAO-A B, IL4I1, KDM1B >100uM, SMOX 7uM). Treatment of THP-1 (MLL-AF9) cells with ORY-1001, results in a time dose dependent me2H3K4 accumulation a

17R(18S)-EpETE is an oxylipin and a cytochrome P450 metabolite of eicosapentaenoic acid .1,217R(18S)-EpETE is an activator of large-conductance calcium-activated potassium (BKCa) channels, increasing the potassium current amplitude by 15-fold in isolated rat cerebral artery vascular smooth muscle cells (VSMCs) at +60 mV when used at a concentration of 50 nM.2It has negative chronotropic effects in isolated neonatal rat cardiomyocytes (NRCMs; EC50= ~1-2 nM) and prevents calcium-induced increases in the spontaneous beating of NRCMs.3,4 1.Schwarz, D., Kisselev, P., Ericksen, S.S., et al.Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: Highly steroselective formation of 17(R), 18(S)-epoxyeicosatetraenoic acidBiochem. Pharmacol.67(8)1445-1457(2004) 2.Lauterbach, B., Barbosa-Sicard, E., Wang, M.H., et al.Cytochrome P450-dependent eicosapentaenoic acid metabolites are novel BK channel activatorsHypertension39(2 Pt. 2)609-613(2002) 3.Falck, J.R., Wallukat, G., Puli, N., et al.17(R),18(S)-Epoxyeicosatetraenoic acid, a potent eicosapentaenoic acid (EPA) derived regulator of cardiomyocyte contraction: Structure-activity relationships and stable analoguesJ. Med. Chem.54(12)4109-4118(2011) 4.Arnold, C., Markovic, M., Blossey, K., et al.Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of omega-3 fatty acidsJ. Biol. Chem.285(43)32720-32733(2010)